PharmaLogic Expands Production with New PET Facility in Atlanta, Georgia

PharmaLogic Holdings Corp., a prominent player in the contract development and manufacturing organization (CDMO) sector, has recently celebrated the opening of its state-of-the-art PET radiopharmaceutical manufacturing facility in Atlanta, Georgia. This new plant signifies a noteworthy commitment to enhancing domestic infrastructure for radiopharmaceuticals, aiming to increase patient access to innovative diagnostic and therapeutic options across the Southeastern United States and beyond.

A Strategic Investment

Underlining the importance of this development, Etienne Montagut, the President and CEO of PharmaLogic, emphasized that the opening of the Atlanta facility is a critical milestone in the company's ongoing $250 million investment to remedy the apparent shortage of radiopharmaceutical manufacturing capabilities in the country. The cutting-edge facility is designed to meet the rising demand for advanced radiopharmaceuticals, making them readily available to patients who rely on these life-saving innovations.

This new hub not only stands to support the immediate health needs of the region but is also set to be pivotal in advancing the research and development of next-generation radiopharmaceuticals. By harnessing advanced PET manufacturing technology, PharmaLogic is poised to expand its production capacity while also dedicating resources specifically to research.

Connecting Healthcare with Innovation

Atlanta's strategic location plays a vital role in PharmaLogic's logistics, allowing for faster and more reliable distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across the area. As the demand for these products continues to grow, having a facility that can swiftly address this need is paramount.

PharmaLogic's Atlanta facility is part of a broader national expansion roll-out, following the success of similar establishments in cities including Cincinnati, Ohio; the Bronx, New York; Salt Lake City, Utah; and Los Angeles, California. This deliberate and expansive strategy illustrates PharmaLogic's commitment to creating a comprehensive platform for radiopharmaceutical manufacturing and distribution that prioritizes scalable patient access to essential healthcare solutions.

Delivering over 2.5 million doses annually, PharmaLogic's operations underscore its resolve to provide healthcare providers and patients with the highest quality radiopharmaceuticals. This new facility is seen as an extension of dedicated efforts to bolster the healthcare system, focusing on enriching patient lives through advanced medical solutions.

About PharmaLogic Holdings Corp.

PharmaLogic leads the industry as a global CDMO specializing in radiopharmaceuticals targeting both diagnostic and therapeutic needs. With decades of rich industry experience and a robust infrastructure that includes over 45 facilities across the United States, Puerto Rico, Canada, and Norway, PharmaLogic assures that its products meet the highest standards of quality and regulatory compliance.

The company is also at the forefront of leveraging cutting-edge technologies to expand its diagnostics business, specifically within oncology, cardiology, and neurology sectors. In terms of therapeutic offerings, PharmaLogic stands as the world’s only cGMP-compliant CDMO that produces and distributes a commercial therapeutic radiopharmaceutical across more than 30 countries globally.

By fostering strategic development partnerships with innovators in the pharmaceutical sector, PharmaLogic is dedicated to enhancing access to radiopharmaceutical products, thereby supporting the pharmaceutical industry's evolution. Those interested can find more details by visiting pharmalogicgroup.com and following the company on LinkedIn for updates on their latest innovations and offerings.